Immunocore (IMCR) Competitors $34.42 -0.82 (-2.33%) Closing price 04:00 PM EasternExtended Trading$34.47 +0.05 (+0.15%) As of 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMCR vs. GRFS, RYTM, LEGN, ABVX, RNA, CYTK, AXSM, NUVL, TGTX, and MRUSShould you be buying Immunocore stock or one of its competitors? The main competitors of Immunocore include Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Legend Biotech (LEGN), Abivax (ABVX), Avidity Biosciences (RNA), Cytokinetics (CYTK), Axsome Therapeutics (AXSM), Nuvalent (NUVL), TG Therapeutics (TGTX), and Merus (MRUS). These companies are all part of the "pharmaceutical products" industry. Immunocore vs. Its Competitors Grifols Rhythm Pharmaceuticals Legend Biotech Abivax Avidity Biosciences Cytokinetics Axsome Therapeutics Nuvalent TG Therapeutics Merus Grifols (NASDAQ:GRFS) and Immunocore (NASDAQ:IMCR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership. Is GRFS or IMCR more profitable? Grifols has a net margin of 0.00% compared to Immunocore's net margin of -5.70%. Grifols' return on equity of 0.00% beat Immunocore's return on equity.Company Net Margins Return on Equity Return on Assets GrifolsN/A N/A N/A Immunocore -5.70%-5.40%-1.93% Do analysts recommend GRFS or IMCR? Grifols presently has a consensus price target of $10.30, indicating a potential upside of 6.96%. Immunocore has a consensus price target of $56.89, indicating a potential upside of 65.28%. Given Immunocore's higher possible upside, analysts clearly believe Immunocore is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grifols 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.60Immunocore 1 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.45 Does the media refer more to GRFS or IMCR? In the previous week, Grifols and Grifols both had 6 articles in the media. Immunocore's average media sentiment score of 0.97 beat Grifols' score of 0.81 indicating that Immunocore is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunocore 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in GRFS or IMCR? 84.5% of Immunocore shares are held by institutional investors. 0.2% of Grifols shares are held by insiders. Comparatively, 10.4% of Immunocore shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more volatility & risk, GRFS or IMCR? Grifols has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Which has preferable earnings & valuation, GRFS or IMCR? Grifols has higher revenue and earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGrifols$7.81B0.85$169.80M$1.178.23Immunocore$310.20M5.59-$51.09M-$0.40-86.05 SummaryGrifols beats Immunocore on 8 of the 15 factors compared between the two stocks. Get Immunocore News Delivered to You Automatically Sign up to receive the latest news and ratings for IMCR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMCR vs. The Competition Export to ExcelMetricImmunocoreMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.78B$3.11B$5.75B$10.24BDividend YieldN/A2.32%5.69%4.60%P/E RatioN/A21.3874.9326.41Price / Sales5.59224.82452.3586.56Price / CashN/A44.4425.8129.91Price / Book4.789.6413.256.28Net Income-$51.09M-$53.20M$3.29B$270.38M7 Day Performance-6.06%0.44%0.47%2.70%1 Month Performance4.68%4.26%4.60%5.99%1 Year Performance2.59%9.43%73.42%25.94% Immunocore Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMCRImmunocore1.8698 of 5 stars$34.42-2.3%$56.89+65.3%+5.0%$1.78B$310.20M0.00320News CoverageGRFSGrifols4.0879 of 5 stars$10.11-0.2%$10.30+1.9%+6.7%$6.96B$7.81B8.6423,822Positive NewsRYTMRhythm Pharmaceuticals3.2826 of 5 stars$99.77-2.3%$101.57+1.8%+93.9%$6.78B$130.13M-33.15140Positive NewsLEGNLegend Biotech3.1979 of 5 stars$34.62-4.0%$74.22+114.4%-34.2%$6.66B$627.24M-39.342,609Positive NewsABVXAbivax2.3891 of 5 stars$90.00+2.2%$92.33+2.6%+616.8%$6.65BN/A0.0061News CoverageEarnings ReportAnalyst ForecastShort Interest ↑Gap DownRNAAvidity Biosciences2.1154 of 5 stars$48.05-4.6%$67.00+39.4%+7.3%$6.48B$10.73M-13.50190Analyst ForecastCYTKCytokinetics4.3838 of 5 stars$52.09-1.7%$75.38+44.7%-8.5%$6.34B$18.47M-10.21250Positive NewsInsider TradeAXSMAxsome Therapeutics4.9088 of 5 stars$129.29+3.3%$177.86+37.6%+26.4%$6.25B$385.69M-25.50380Positive NewsNUVLNuvalent3.1543 of 5 stars$79.83-1.3%$120.91+51.5%-8.0%$5.83BN/A-16.2940Positive NewsInsider TradeTGTXTG Therapeutics4.3059 of 5 stars$32.38+0.5%$46.25+42.8%+35.5%$5.11B$329M87.51290Insider TradeMRUSMerus2.8032 of 5 stars$67.19-0.4%$88.75+32.1%+38.8%$5.10B$36.13M-12.2237Positive News Related Companies and Tools Related Companies GRFS Competitors RYTM Competitors LEGN Competitors ABVX Competitors RNA Competitors CYTK Competitors AXSM Competitors NUVL Competitors TGTX Competitors MRUS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMCR) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunocore Holdings PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunocore With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMCR Stock Alerts